Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00115453|
Recruitment Status : Terminated (Slow accrual)
First Posted : June 23, 2005
Last Update Posted : August 18, 2008
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Radiation: irradiation||Phase 1 Phase 2|
This is a single BNCT-facility, non-randomized, non-comparative, prospective, open-label, phase I/II trial to determine the value of BNCT in the treatment of subjects who have undergone surgery for glioblastoma, but glioblastoma has not been treated with radiation therapy or chemotherapy. The neutron irradiation site is the FiR 1 reactor site, located at Otaniemi, Espoo, Finland, about 6 kilometers from the Helsinki University Central Hospital, Helsinki, where patient evaluation and post-irradiation care will take place.
BPA is infused as a fructose complex (BPA-F) into a peripheral vein over 2 hours prior to neutron irradiation. Blood samples will be taken before starting the BPA infusion, and thereafter at 20 to 40 minute intervals during the infusion, following infusion, and after delivering neutron irradiation to monitor the blood boron concentration. The blood samples will be analyzed for boron to estimate the average blood boron level during neutron irradiation. The first 12 patients are treated using a BPA dose of 290 mg/kg, following which the dose of BPA is increased stepwise to 500 mg/kg, provided that unacceptable toxicity will not occur.
All patients will be evaluated for response using CT or magnetic resonance imaging (MRI).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Boron Neutron Capture Therapy in the Treatment of Glioblastoma Multiforme|
|Study Start Date :||May 1999|
|Primary Completion Date :||August 2008|
|Study Completion Date :||August 2008|
Active treatment arm.
Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
- safety [ Time Frame: 3 years ]
- tumor response [ Time Frame: one year ]
- effect on brain tissue [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115453
|Department of Oncology, Helsinki University Central Hospital|
|Helsinki, Finland, FIN-00029|
|Principal Investigator:||Heikki Joensuu, M.D., prof.||Helsinki University Central Hospital|